PH12021550832A1 - Combination of small molecule cd-47 inhibitors with other anti-cancer agents - Google Patents

Combination of small molecule cd-47 inhibitors with other anti-cancer agents

Info

Publication number
PH12021550832A1
PH12021550832A1 PH12021550832A PH12021550832A PH12021550832A1 PH 12021550832 A1 PH12021550832 A1 PH 12021550832A1 PH 12021550832 A PH12021550832 A PH 12021550832A PH 12021550832 A PH12021550832 A PH 12021550832A PH 12021550832 A1 PH12021550832 A1 PH 12021550832A1
Authority
PH
Philippines
Prior art keywords
combination
inhibitors
small molecule
cancer agents
cancer
Prior art date
Application number
PH12021550832A
Other languages
English (en)
Inventor
Muralidhara Ramachandra
Pottayil Govindan Nair Sasikumar
Girish Chandrappa Daginakatte
Kiran Aithal Balkudru
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of PH12021550832A1 publication Critical patent/PH12021550832A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PH12021550832A 2018-11-08 2021-04-13 Combination of small molecule cd-47 inhibitors with other anti-cancer agents PH12021550832A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841042108 2018-11-08
PCT/IB2019/059602 WO2020095256A1 (en) 2018-11-08 2019-11-08 Combination of small molecule cd-47 inhibitors with other anti-cancer agents

Publications (1)

Publication Number Publication Date
PH12021550832A1 true PH12021550832A1 (en) 2021-10-04

Family

ID=69159806

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550832A PH12021550832A1 (en) 2018-11-08 2021-04-13 Combination of small molecule cd-47 inhibitors with other anti-cancer agents

Country Status (14)

Country Link
US (3) US11311517B2 (https=)
EP (1) EP3876931A1 (https=)
JP (2) JP7623279B2 (https=)
KR (1) KR20210088584A (https=)
CN (2) CN112930181B (https=)
AU (1) AU2019375193A1 (https=)
BR (1) BR112021008781A2 (https=)
CA (1) CA3118843A1 (https=)
EA (1) EA202190776A1 (https=)
IL (1) IL282972B2 (https=)
MX (2) MX2021005240A (https=)
PH (1) PH12021550832A1 (https=)
SG (1) SG11202104192TA (https=)
WO (1) WO2020095256A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737401A4 (en) * 2018-01-12 2021-09-15 Aurigene Discovery Technologies Limited 1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF THE CD47 SIGNAL PATH
EP4291238A4 (en) * 2021-02-10 2024-10-09 Great Novel Therapeutics Biotech & Medicals Corporation PHARMACEUTICAL COMBINATION AND METHOD FOR OVERCOMING IMMUNE SUPPRESSION OR STIMULATING AN IMMUNE RESPONSE AGAINST CANCER
CN113018415B (zh) * 2021-03-17 2022-07-01 遵义医科大学 一种药物组合及其应用
CN113750215B (zh) * 2021-09-24 2023-06-23 暨南大学 用于治疗肿瘤的联合药物
WO2025083628A1 (en) 2023-10-19 2025-04-24 Aurigene Oncology Limited Pharmaceutically acceptable salt of a cd47-sirp alpha pathway inhibitor
WO2025229631A2 (en) * 2024-05-03 2025-11-06 Aurigene Oncology Limited A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER
US20250339404A1 (en) 2024-05-03 2025-11-06 Aurigene Oncology Limited COMBINATION THERAPY USING A CD47-SIRP alpha BLOCKING AGENT AND AZACITIDINE
CN118453879B (zh) * 2024-05-23 2025-10-03 大连医科大学附属第二医院 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2672828A1 (en) * 2006-12-13 2008-06-26 Schering Corporation Methods of treatment
HRP20221260T1 (hr) 2010-05-14 2023-03-03 The Board Of Trustees Of The Leland Stanford Junior University Humanizirana i kimerna monoklonska protutijela za cd47
HRP20181052T1 (hr) 2013-09-06 2018-09-07 Aurigene Discovery Technologies Limited Derivati 1,2,4-oksadiazola kao imunomodulatori
EP3267985A4 (en) 2015-03-10 2018-07-25 Aurigene Discovery Technologies Limited 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
NZ734650A (en) * 2015-03-10 2023-07-28 Aurigene Oncology Ltd 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2016168246A1 (en) 2015-04-14 2016-10-20 The Procter & Gamble Company Solid conditioning composition
CN104804093A (zh) 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
NZ741324A (en) 2015-09-21 2021-09-24 Erasmus Univ Medical Center Anti-cd47 antibodies and methods of use
EP3243522A1 (en) 2016-05-10 2017-11-15 Université Pierre et Marie Curie (Paris 6) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
DK3454879T3 (da) 2016-05-10 2022-03-14 Inst Nat Sante Rech Med Hidtil ukendte forbindelser og farmaceutisk anvendelse deraf i behandlingen af kræft
WO2018047139A1 (en) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
MY205585A (en) * 2016-10-20 2024-10-28 Aurigene Oncology Ltd Dual inhibitors of vista and pd-1 pathways
EP3737401A4 (en) * 2018-01-12 2021-09-15 Aurigene Discovery Technologies Limited 1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF THE CD47 SIGNAL PATH
WO2019175799A2 (en) * 2018-03-14 2019-09-19 Aurigene Discovery Technologies Limited Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds

Also Published As

Publication number Publication date
CA3118843A1 (en) 2020-05-14
IL282972B1 (en) 2025-02-01
CN112930181B (zh) 2025-05-13
IL282972A (en) 2021-06-30
EP3876931A1 (en) 2021-09-15
CN112930181A (zh) 2021-06-08
AU2019375193A1 (en) 2021-05-13
JP2022507025A (ja) 2022-01-18
US20250177358A1 (en) 2025-06-05
EA202190776A1 (ru) 2021-09-20
US20220241248A1 (en) 2022-08-04
JP2025063207A (ja) 2025-04-15
KR20210088584A (ko) 2021-07-14
US20200147054A1 (en) 2020-05-14
US12268670B2 (en) 2025-04-08
JP7623279B2 (ja) 2025-01-28
IL282972B2 (en) 2025-06-01
BR112021008781A2 (pt) 2021-08-03
SG11202104192TA (en) 2021-05-28
MX2021005240A (es) 2021-06-18
US11311517B2 (en) 2022-04-26
MX2024006094A (es) 2024-05-30
WO2020095256A1 (en) 2020-05-14
CN120305258A (zh) 2025-07-15

Similar Documents

Publication Publication Date Title
PH12021550832A1 (en) Combination of small molecule cd-47 inhibitors with other anti-cancer agents
EA202190630A1 (ru) Способы комбинированной терапии
SA522433087B1 (ar) Sos1 مثبطات
MX2024004215A (es) Terapias combinadas de inhibidores de kras g12d con inhibidores de sos1.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
MX2025011553A (es) Composiciones para inducir la hidrolisis de ras gtp y sus usos
EA202190749A1 (ru) Способы комбинированной терапии
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
NZ726366A (en) Syk inhibitors
PH12023550160A1 (en) Combinations for the Treatment of Cancer
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
NZ749997A (en) Combination of a pd-l antagonist and a raf inhibitor for treating cancer
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2020007403A (es) Compuestos de tetrahidroisoquinolina.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2019136157A3 (en) Reducing beta-catenin and ido expression to potentiate immunotherapy
MX2021009535A (es) Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación.
MY206479A (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX2025003004A (es) Formas farmaceuticas de un inhibidor de cd73
MX2023008796A (es) Métodos para el tratamiento del trastorno del habla en niños.
MX2023009620A (es) Metodos terapeuticos.
MX2023000151A (es) Terapia de combinacion de verapamilo y mometasona para el tratamiento de rinosinusitis cronica.